Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

Allan Lipton, Harold Harvey, R. J. Santen, A. Boucher, D. White, A. Bernath, R. Dixon, G. Richards, A. Shafik

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

Original languageEnglish (US)
JournalCancer Research
Volume42
Issue number8 Suppl.
StatePublished - Dec 1 1982

Fingerprint

Aminoglutethimide
Tamoxifen
Breast Neoplasms
Estrogen Receptor Modulators
Hydrocortisone
Neoplasms
Estrogens
Bone and Bones
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lipton, A., Harvey, H., Santen, R. J., Boucher, A., White, D., Bernath, A., ... Shafik, A. (1982). Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Research, 42(8 Suppl.).
Lipton, Allan ; Harvey, Harold ; Santen, R. J. ; Boucher, A. ; White, D. ; Bernath, A. ; Dixon, R. ; Richards, G. ; Shafik, A. / Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. In: Cancer Research. 1982 ; Vol. 42, No. 8 Suppl.
@article{940c68c0a4684fa99f2b0f243c4aaab7,
title = "Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer",
abstract = "We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38{\%}) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36{\%}) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.",
author = "Allan Lipton and Harold Harvey and Santen, {R. J.} and A. Boucher and D. White and A. Bernath and R. Dixon and G. Richards and A. Shafik",
year = "1982",
month = "12",
day = "1",
language = "English (US)",
volume = "42",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8 Suppl.",

}

Lipton, A, Harvey, H, Santen, RJ, Boucher, A, White, D, Bernath, A, Dixon, R, Richards, G & Shafik, A 1982, 'Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer', Cancer Research, vol. 42, no. 8 Suppl..

Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. / Lipton, Allan; Harvey, Harold; Santen, R. J.; Boucher, A.; White, D.; Bernath, A.; Dixon, R.; Richards, G.; Shafik, A.

In: Cancer Research, Vol. 42, No. 8 Suppl., 01.12.1982.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

AU - Lipton, Allan

AU - Harvey, Harold

AU - Santen, R. J.

AU - Boucher, A.

AU - White, D.

AU - Bernath, A.

AU - Dixon, R.

AU - Richards, G.

AU - Shafik, A.

PY - 1982/12/1

Y1 - 1982/12/1

N2 - We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

AB - We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

UR - http://www.scopus.com/inward/record.url?scp=0020328459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020328459&partnerID=8YFLogxK

M3 - Article

C2 - 7044526

AN - SCOPUS:0020328459

VL - 42

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8 Suppl.

ER -

Lipton A, Harvey H, Santen RJ, Boucher A, White D, Bernath A et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Research. 1982 Dec 1;42(8 Suppl.).